Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase

T. Spelman, S. Eichau, R. Alroughani, S. Ozakbas, SJ. Khoury, F. Patti, E. Kubala Havrdova, C. Boz, M. Terzi, J. Kuhle, P. Grammond, J. Lechner-Scott, O. Gray, MP. Amato, G. Laureys, V. Shaygannejad, R. Hyde, H. Wang, I. Bozin, N. Belviso, C....

. 2024 ; 10 (2) : 20552173241247182. [pub] 20240525

Status not-indexed Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24012703

BACKGROUND: The use of non-specific immunosuppressants (NSIS) to treat multiple sclerosis (MS) remains prevalent in certain geographies despite safety concerns, likely due to resource limitations. OBJECTIVE: To use MSBase registry data to compare real-world outcomes in adults with relapsing-remitting MS (RRMS) treated with dimethyl fumarate (DMF) or NSIS (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mitoxantrone or mycophenolate mofetil) between January 1, 2014 and April 1, 2022. METHODS: Treatment outcomes were compared using inverse probability of treatment weighting (IPTW) Cox regression. Outcomes were annualized relapse rates (ARRs), time to discontinuation, time to first relapse (TTFR) and time to 24-week confirmed disability progression (CDP) or 24-week confirmed disability improvement (CDI; in patients with baseline Expanded Disability Status Scale [EDSS] score ≥2). RESULTS: After IPTW, ARR was similar for DMF (0.13) and NSIS (0.16; p = 0.29). There was no difference in TTFR between cohorts (hazard ratio [HR]: 0.98; p = 0.84). The DMF cohort experienced longer times to discontinuation (HR: 0.75; p = 0.001) and CDP (HR: 0.53; p = 0.001), and shorter time to CDI (HR: 1.99; p < 0.008), versus the NSIS cohort. CONCLUSION: This analysis supports the use of DMF to treat patients with relapsing forms of MS, and may have implications for MS practices in countries where NSIS are commonly used to treat RRMS.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24012703
003      
CZ-PrNML
005      
20240726151326.0
007      
ta
008      
240723s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/20552173241247182 $2 doi
035    __
$a (PubMed)38800132
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Spelman, Tim $u MSBase Foundation, Melbourne, Australia $u Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden $1 https://orcid.org/0000000192043216
245    10
$a Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase / $c T. Spelman, S. Eichau, R. Alroughani, S. Ozakbas, SJ. Khoury, F. Patti, E. Kubala Havrdova, C. Boz, M. Terzi, J. Kuhle, P. Grammond, J. Lechner-Scott, O. Gray, MP. Amato, G. Laureys, V. Shaygannejad, R. Hyde, H. Wang, I. Bozin, N. Belviso, C. Quan, F. Zeng, A. van der Walt, H. Butzkueven, MSBase Study Group
520    9_
$a BACKGROUND: The use of non-specific immunosuppressants (NSIS) to treat multiple sclerosis (MS) remains prevalent in certain geographies despite safety concerns, likely due to resource limitations. OBJECTIVE: To use MSBase registry data to compare real-world outcomes in adults with relapsing-remitting MS (RRMS) treated with dimethyl fumarate (DMF) or NSIS (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mitoxantrone or mycophenolate mofetil) between January 1, 2014 and April 1, 2022. METHODS: Treatment outcomes were compared using inverse probability of treatment weighting (IPTW) Cox regression. Outcomes were annualized relapse rates (ARRs), time to discontinuation, time to first relapse (TTFR) and time to 24-week confirmed disability progression (CDP) or 24-week confirmed disability improvement (CDI; in patients with baseline Expanded Disability Status Scale [EDSS] score ≥2). RESULTS: After IPTW, ARR was similar for DMF (0.13) and NSIS (0.16; p = 0.29). There was no difference in TTFR between cohorts (hazard ratio [HR]: 0.98; p = 0.84). The DMF cohort experienced longer times to discontinuation (HR: 0.75; p = 0.001) and CDP (HR: 0.53; p = 0.001), and shorter time to CDI (HR: 1.99; p < 0.008), versus the NSIS cohort. CONCLUSION: This analysis supports the use of DMF to treat patients with relapsing forms of MS, and may have implications for MS practices in countries where NSIS are commonly used to treat RRMS.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Eichau, Sara $u Hospital Universitario Virgen Macarena, Sevilla, Spain $1 https://orcid.org/0000000191593128
700    1_
$a Alroughani, Raed $u Amiri Hospital, Sharq, Kuwait
700    1_
$a Ozakbas, Serkan $u Dokuz Eylul University, Konak/Izmir, Turkey
700    1_
$a Khoury, Samia J $u American University of Beirut Medical Center, Beirut, Lebanon
700    1_
$a Patti, Francesco $u Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania, Italy $1 https://orcid.org/0000000269230846
700    1_
$a Kubala Havrdova, Eva $u Department of Neurology, First Medical Faculty, Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Boz, Cavit $u KTU Medical Faculty Farabi Hospital, Trabzon, Turkey
700    1_
$a Terzi, Murat $u 19 Mayis University, Samsun, Turkey
700    1_
$a Kuhle, Jens $u Department of Neurology, University Hospital and University of Basel, Basel, Switzerland $u Multiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland
700    1_
$a Grammond, Pierre $u CISSS Chaudière-Appalache, Lévis, QC, Canada
700    1_
$a Lechner-Scott, Jeanette $u University of Newcastle, Newcastle, NSW, Australia
700    1_
$a Gray, Orla $u South Eastern HSC Trust, Belfast, UK $1 https://orcid.org/0000000277990116
700    1_
$a Amato, Maria Pia $u University of Florence, Florence, Italy $1 https://orcid.org/0000000333253760
700    1_
$a Laureys, Guy $u University Hospital Ghent, Ghent, Belgium
700    1_
$a Shaygannejad, Vahid $u Isfahan University of Medical Sciences, Isfahan, Iran
700    1_
$a Hyde, Robert $u Biogen, Baar, Switzerland
700    1_
$a Wang, Haijue $u Biogen, Cambridge, MA, USA
700    1_
$a Bozin, Ivan $u Biogen, Baar, Switzerland
700    1_
$a Belviso, Nicholas $u Biogen, Cambridge, MA, USA
700    1_
$a Quan, Chao $u Department of Neurology, Huashan Hospital, National Center for Neurological Disorders, Fudan University, Shanghai, China $1 https://orcid.org/0000000310403930
700    1_
$a Zeng, Feng $u Biogen, Cambridge, MA, USA
700    1_
$a van der Walt, Anneke $u Monash University, Melbourne, Australia $1 https://orcid.org/0000000242787003
700    1_
$a Butzkueven, Helmut $u The Alfred Hospital, Melbourne, Australia
710    2_
$a MSBase Study Group
773    0_
$w MED00194908 $t Multiple sclerosis journal - experimental, translational and clinical $x 2055-2173 $g Roč. 10, č. 2 (2024), s. 20552173241247182
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38800132 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151319 $b ABA008
999    __
$a ok $b bmc $g 2125449 $s 1224566
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 10 $c 2 $d 20552173241247182 $e 20240525 $i 2055-2173 $m Multiple sclerosis journal - experimental, translational and clinical $n Mult Scler J Exp Transl Clin $x MED00194908
LZP    __
$a Pubmed-20240723

Find record

Citation metrics

Archiving options